Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CLOFARABINE Clear all

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions: Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity); Drug
Lead sponsor: Targazyme, Inc.; Industry
Eligibility: 1 Year to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more

Conditions: Myelodysplastic Syndromes
Interventions: Clofarabine; Drug
Lead sponsor: Texas Oncology Cancer Center; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Crohn Disease
Interventions: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab; Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia
Interventions: clofarabine, cytarabine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 16 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 91
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Orange, California + 54 more

Conditions: Leukemia, Lymphoma, Small Intestine Cancer
Interventions: clofarabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 2 Years to 120 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 3
States / cities: New York, New York • Rochester, New York • Cleveland, Ohio

Conditions: Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hodgkin or Non-Hodgkin Lymphoma, Sarcoma, Myeloid
Interventions: clofarabine, cytarabine, busulfan, Plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, Tacrolimus, mycophenolate mofetil; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Solid Tumors
Interventions: clofarabine (oral formulation); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Dallas, Texas • Tyler, Texas • Spokane, Washington

Conditions: Myelodysplastic Syndromes
Interventions: filgrastim, clofarabine, cytarabine, microarray analysis, biopsy; Biological · Drug · Genetic + 1 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: clofarabine, melphalan, gene expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 1 Year to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Duarte, California

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions: Clofarabine, Cytarabine, Thymoglobulin, Stem cell infusion; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myelogenous Leukemia
Interventions: clofarabine (IV formulation); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 9 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Clofarabine, Fludarabine, Hematopoietic Cell Transplantation, Total-Body Irradiation, Treosulfan, Echocardiography Test, Multigated Acquisition Scan, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection; Drug · Procedure · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Langerhans Cell Histiocytosis
Interventions: Clofarabine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions: clofarabine, cyclophosphamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 2 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkins Disease, Non-Hodgkins Lymphoma, Aplastic Anemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Busulfan, Clofarabine, Fludarabine, Melphalan, Carmustine, Etoposide, Cytarabine; Drug
Lead sponsor: Texas Oncology Cancer Center; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Myelodysplastic Syndromes
Interventions: clofarabine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Tampa, Florida • Rochester, Minnesota • San Antonio, Texas

Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions: clofarabine, Ara-C; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF; Procedure · Drug · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
Interventions: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide, Ofatumumab, Pegfilgrastim, Rituximab, Vincristine Sulfate Liposome; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions: Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions: CAR T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult, Myelodysplastic Syndromes, Adult
Interventions: clofarabine (IV formulation); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Dallas, Texas • Tyler, Texas

Search by objective public record fields.

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Cord Blood Expansion on Mesenchymal Stem Cells

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

HSCT for High Risk Inherited Inborn Errors

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Clofarabine in Adult Patients With Advanced Solid Tumors